Companies Announce Financial Results, Testing, Clinic, Earnings Date
Tap title to read story
Stamford, Conn. and multiple U.S. and UK locations — On April 21, 2026, Aircastle reported improved fiscal 2025 profitability, 46 aircraft acquisitions adding $1.7 billion NBV and gains of $96 million from 33 aircraft sales; Nauticus completed simulated intervention testing in Robert, Louisiana; Northwest Biotherapeutics announced a new leukapheresis clinic in London; Qorvo scheduled Q4 results for May 5, 2026.
The announcements carry immediate operational and investor implications: Aircastle cited ratings upgrades and warned of Middle East-related fuel-cost risks while planning continued fleet investment into 2026; Nauticus validated tooling and safety mitigations ahead of East Coast deployments; Qorvo halted guidance pending its Skyworks transaction and set a May 5 release; Northwest expects increased leukapheresis capacity and potential service provision for others.
More context
Timeline
- 1. Feb 28, 2026 — Aircastle reported owning 277 aircraft with $8.5 billion net book value.
- 2. April 21, 2026 — Aircastle announced fiscal 2025 results citing acquisitions, NBV additions, and sale gains.
- 3. April 21, 2026 — Nauticus completed Simulated Intervention Testing at its Robert, Louisiana facility.
- 4. April 21, 2026 — Northwest Biotherapeutics announced establishment of a leukapheresis clinic at The London Welbeck Hospital.
- 5. May 5, 2026 — Qorvo will distribute fiscal Q4 2026 financial results at approximately 4:00 p.m. ET.
Why it matters
Aircastle's growth may affect your travel costs. If you're an investor, note their Middle East fuel-cost risks. Nauticus' testing could impact East Coast operations. If you're in London, Northwest's new clinic could offer more health services. Qorvo's upcoming results may influence tech stock trends.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
